Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1NET 1Endocrine 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 2Vaccinia 1Uterine Cervical Neoplasms 1Neuroendocrine Tumors 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 115Carboplatin 114Cisplatin 46Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28Bevacizumab 28liposomal doxorubicin 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 13sargramostim 12olaparib 12Immunohistochemistry 11Chemotherapy, Adjuvant 11Surgical Procedures, Operative 10Therapeutics 9Flow Cytometry 9Etoposide 9oregovomab 8niraparib 8mirvetuximab soravtansine 8Psychiatric Rehabilitation 8Nivolumab 8Amifostine 8rucaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × taxane × Gynecologic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00293293 2017-12-28

Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine

Masonic Cancer Center, University of Minnesota

Phase NA Completed
43 enrolled 22 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡